Member Info for researcher1

social media has been lively with reports that Jupiter have left the building! hurrah! GLA

methinks we could do with hearing good news from Corteva.....

I like the way no one wants to post any more. It is such a positive sign. Everyone knows what this is about, and when it will happen. The research data is world leading. The idiotic selling of a distressed institution is pitiable. The MCAP is tiny. Hold tight for 2021 Anglists. GLA

provides even more confidence. I'm looking forward to the next revenue guidance...

just the way AIM works Dibs - we just have to make it work for us.....

well, half your house. I still have enough for a big shed.

good attitude chimers - I've got half a house sale in recently, at 40p - the rest of my holding is @ 49p however, so I'm not even vaguely going to think of a top slice until we are in the high 50s. I will likely hold onto the lot until I need the money in a year's time. Hopefully £4 by then :-)

so the previous rise was a ruse to allow Jupiter to get a better price - well played MMs.

yes, there can be a delayed reaction, but as I'm waiting for next spring I don't really care.... It is what happens when the SP is around 60 prior to the FDA news when it will get interesting. I will enjoy sticking a finger up to Jupiter in particular - if Angle had not been so far advanced in its research, actions such as theirs could destroy a company.

.... how this goes down on great news - who is the culprit today? I feel sorry for them, with the best to come so soon....

chimers, can you explain "green stripe" please?

well, having said that, it does look like there is selling into the rise.....

one cell isolated with a sample with one cell in it - now that's what I call precision (and accuracy). I also like the fact the company are happy to release it - I doubt they'd want Jupiter to benefit from an uplift, so my supposition is they are out.

bought back in today - great price - look forward to the revenue update!

I'm planning to put my 50% top slice (@36) back in today - or should I wait for Boris to sort things out with Europe? (ha ha)

thanks bojo - always good to see the CEO with a fair chunk....

Bojo that doesn't make sense - i.e. it is not current. Jupiter issued a TR1 in November reducing them from almost 10% to under 5% - which would mean under 10M shares - this chart says 17M....

scotlouie, you justly correct me - breast cancer is of course first (I said ovarian, which is the next one in the pipeline). Like you I've not heard the BoD mention any scaling production line issues...

hi Chester,

There are already substantial stocks of both Parsortix machines and especially cassettes, partly because there is already robust research use, and partly in anticipation of FDA approval. There has not been any talk (I can recall) of 'scaling up' manufacture, as they are relatively easy to build, and demand is expected to rise gradually rather than in a huge rush, though 'healthy' initial orders for ovarian cancer diagnosis are expected. The Parsortix system itself retails at around £50K (of which 70% is profit), and the cassettes £100 each (£85% profit). Each machine can run a cassette every 30 minutes, continuously, so I guess that would be between £2500 and £5000 worth of cassettes per machine, per day, depending upon urgency. Once Angle has its own clinics and downstream analysis, the revenue figures increase significantly. The clinics should be ready for FDA approval (as it stated so in the fundraising RNS). It would be interesting to hear any added detail you get from emailing the company. Good luck!

moon, we had this discussion earlier - market size for liquid biopsy is approximately $8B pa. Angle will be market leader post-FDA, MCAP 80M - so there is room for a 100 fold increase! But £40 per share may take a little while.